{"name":"Indivior","slug":"indivior","ticker":"INDV.L","exchange":"LSE","domain":"indivior.com","description":"Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.","hq":"Slough, United Kingdom","founded":2002,"employees":"~1,000","ceo":"Mark Crossley","sector":"Specialty Pharma / Addiction Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"0","metrics":{"revenue":1239000000,"revenueGrowth":4.3,"grossMargin":0,"rdSpend":0,"netIncome":210000000,"cash":1201000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","revenue":800000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1981-01-01","label":"Subutex first approved","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-23","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2027-07-23","label":"Subutex patent expiry (Formulation)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-12-21","label":"Subutex patent expiry (Method of Use)","drug":"Subutex","drugSlug":"buprenorphine-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Suboxone patent cliff ($1.1B at risk)","drug":"Suboxone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":800000000,"percentOfTotal":100,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","indication":"Acute postoperative pain","status":"marketed","revenue":800000000},{"name":"Subutex, Buprenorphine Hydrochloride, SCH 28444","genericName":"Subutex, Buprenorphine Hydrochloride, SCH 28444","slug":"subutex-buprenorphine-hydrochloride-sch-28444","indication":"Opioid use disorder (maintenance treatment and detoxification)","status":"marketed"},{"name":"Buprenorphine (Subutex)","genericName":"Buprenorphine (Subutex)","slug":"buprenorphine-subutex","indication":"Opioid use disorder (maintenance treatment)","status":"marketed"},{"name":"RBP-6000","genericName":"RBP-6000","slug":"rbp-6000","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"},{"name":"TM buprenorphine","genericName":"TM buprenorphine","slug":"tm-buprenorphine","indication":"Opioid use disorder (maintenance treatment)","status":"marketed"},{"name":"Transmucosal Buprenorphine","genericName":"Transmucosal Buprenorphine","slug":"transmucosal-buprenorphine","indication":"Opioid use disorder maintenance treatment","status":"marketed"},{"name":"Zubsolv sublingual tablets","genericName":"Zubsolv sublingual tablets","slug":"zubsolv-sublingual-tablets","indication":"Opioid use disorder maintenance treatment","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"INDV-2000","genericName":"INDV-2000","slug":"indv-2000","indication":"Other","status":"phase_2"},{"name":"Suboxone","genericName":"Suboxone","slug":"suboxone","indication":"Other","status":"marketed"},{"name":"Arbaclofen Placarbil MR Prototype A","genericName":"Arbaclofen Placarbil MR Prototype A","slug":"arbaclofen-placarbil-mr-prototype-a","indication":"Other","status":"phase_1"},{"name":"Buprenorphine soluble film","genericName":"Buprenorphine soluble film","slug":"buprenorphine-soluble-film","indication":"Other","status":"phase_2"},{"name":"Fentanyl - Part B","genericName":"Fentanyl - Part B","slug":"fentanyl-part-b","indication":"Other","status":"phase_1"},{"name":"Nalorex","genericName":"Nalorex","slug":"nalorex","indication":"Other","status":"phase_1"},{"name":"PERSERIS","genericName":"PERSERIS","slug":"perseris","indication":"Other","status":"marketed"},{"name":"SL Buprenorphine","genericName":"SL Buprenorphine","slug":"sl-buprenorphine","indication":"Other","status":"marketed"},{"name":"Suboxone Sublingual Film","genericName":"Suboxone Sublingual Film","slug":"suboxone-sublingual-film","indication":"Other","status":"marketed"},{"name":"Subutex","genericName":"Subutex","slug":"subutex","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"RBP-7000","genericName":"RBP-7000","slug":"rbp-7000","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"Subutex","genericName":"Buprenorphine Hydrochloride","slug":"buprenorphine-hydrochloride","phase":"marketed","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors.","indications":["Acute postoperative pain","Chronic Pain with Opioid Tolerance","Chronic pain","Opioid dependence","Prevention of opioid abuse"],"catalyst":""},{"name":"INDV-2000","genericName":"INDV-2000","slug":"indv-2000","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Suboxone","genericName":"Suboxone","slug":"suboxone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subutex, Buprenorphine Hydrochloride, SCH 28444","genericName":"Subutex, Buprenorphine Hydrochloride, SCH 28444","slug":"subutex-buprenorphine-hydrochloride-sch-28444","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.","indications":["Opioid use disorder (maintenance treatment and detoxification)","Pain management (off-label use in some jurisdictions)"],"catalyst":""},{"name":"Arbaclofen Placarbil MR Prototype A","genericName":"Arbaclofen Placarbil MR Prototype A","slug":"arbaclofen-placarbil-mr-prototype-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buprenorphine (Subutex)","genericName":"Buprenorphine (Subutex)","slug":"buprenorphine-subutex","phase":"marketed","mechanism":"Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists.","indications":["Opioid use disorder (maintenance treatment)","Moderate to severe pain"],"catalyst":""},{"name":"Buprenorphine soluble film","genericName":"Buprenorphine soluble film","slug":"buprenorphine-soluble-film","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fentanyl - Part B","genericName":"Fentanyl - Part B","slug":"fentanyl-part-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nalorex","genericName":"Nalorex","slug":"nalorex","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PERSERIS","genericName":"PERSERIS","slug":"perseris","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RBP-6000","genericName":"RBP-6000","slug":"rbp-6000","phase":"phase_3","mechanism":"RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"RBP-7000","genericName":"RBP-7000","slug":"rbp-7000","phase":"phase_3","mechanism":"RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.","indications":["Schizophrenia","Schizoaffective disorder"],"catalyst":""},{"name":"SL Buprenorphine","genericName":"SL Buprenorphine","slug":"sl-buprenorphine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Suboxone Sublingual Film","genericName":"Suboxone Sublingual Film","slug":"suboxone-sublingual-film","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subutex","genericName":"Subutex","slug":"subutex","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TM buprenorphine","genericName":"TM buprenorphine","slug":"tm-buprenorphine","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","indications":["Opioid use disorder (maintenance treatment)","Moderate to severe pain"],"catalyst":""},{"name":"Transmucosal Buprenorphine","genericName":"Transmucosal Buprenorphine","slug":"transmucosal-buprenorphine","phase":"marketed","mechanism":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","indications":["Opioid use disorder maintenance treatment","Acute pain management","Chronic pain"],"catalyst":""},{"name":"Zubsolv sublingual tablets","genericName":"Zubsolv sublingual tablets","slug":"zubsolv-sublingual-tablets","phase":"marketed","mechanism":"Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.","indications":["Opioid use disorder maintenance treatment"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Indivior Reports Fourth Quarter and Full Year 2023 Results","summary":"Indivior reported revenue of $1.1 billion for the full year 2023, up 5% from the prior year. The company also reported a net loss of $1.4 billion for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Indivior Announces Agreement to Sell Suboxone Business to Dr. Reddy's Laboratories","summary":"Indivior announced an agreement to sell its Suboxone business to Dr. Reddy's Laboratories for $1.1 billion.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"FDA Approves Indivior's Sublocade for Opioid Use Disorder","summary":"The FDA approved Indivior's Sublocade, a medication-assisted treatment for opioid use disorder, for marketing in the US.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQa0VOQkx6cG1KRG1yeGlwWk1OUGpCdG5wN2tHSHlGU2lPQlBSX201NU5haHBjSkYxelM5VFBQQTVEYUotT2UtSFdnUGFxV1JFNTJpR2ZFaWMtS1g0OFg0TmV0cFdZb3dWdi1BY0RYVENmdm4yMGtOUzIyZE5ROTB1clFEekItaTNwWlB5NGNibUFBalEt?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK","headline":"Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE94ZkRzSVBRRURJZ3hPS01VWTFPRW1GRm0zWTJDQXlhZ2FOcHRyWmVhWi0zM1M5aXRlZkhJV296UGJMQ196M3FQZERKVTRrTFdWVE5ESW03TVVRQmVPaWhKVGRlOHMzM1dQaWlDbk1VWnVraGFyRzdjcVFKU1Y?oc=5","date":"2025-08-03","type":"earnings","source":"Yahoo Finance","summary":"Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook - Yahoo Finance","headline":"Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPWElDeWo3S0VQLWRqZ2RjYkRGcS0wS0xJZ2hQcFB4cXpiY3kyUU9Ha3o3RFR6UXQzaFFSa3RRLXY2S2VMRDhmckFXZVNoeUVEWGdqYWxaTnpVQWxndkFOYUJFajZfQzdtc3FDc0RQZGxjV2FtWDR5S0xDTmZLY2tmeld0U0NDNXhEUVA3bQ?oc=5","date":"2025-07-28","type":"pipeline","source":"Yahoo Finance","summary":"Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq - Yahoo Finance","headline":"Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQSmQyc3B6clFuV0RkWVRuc3pBY0psTVg2WUJmU0g1Q1BOZGFOaU5FZGdTV3Rjd1pJY2owYk1yQ1dMbzhsTENxM2NzTnc3NjJrUHV6c3VpY3ZmUkl4NnJLT1hHQm91bU9Eb3N3ZV9JNUk3Q3diOEY4TTcxd01XbFdNYldwMWZRR0ZFUmZJ?oc=5","date":"2025-06-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Drug maker Indivior to abandon London stock market for the US - Yahoo Finance UK","headline":"Drug maker Indivior to abandon London stock market for the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPRGhXcnFZYTRzVnR6X0IxVHY2RGwybG1LLThNU2hybmw2X1NwbVdxdzNsRHZwRUIzdEg4aWhoZGczak41UGVXelAxRktqR3ZvQ0gzcEphd0h2NFE2clBvQl9YNE5nYXFrRWZFMEhETlA4R1JWMUd3bVhIb0FyeWZ4eE01RnNjR0I0alNKUEdGNVExTmUyWHhESTR1TTBwT0ZxeHJtTUh5T1oxT1hkTFVV?oc=5","date":"2025-02-26","type":"pipeline","source":"Reuters","summary":"UK's Indivior appoints Joe Ciaffoni as CEO - Reuters","headline":"UK's Indivior appoints Joe Ciaffoni as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPYWFjR3pmdm8ySGlua1ZwcXdPMk15RVJJQlNFQzRINTNvRFVTTVBtODNhMXFxOWpMUTNpWXk5NHlWanRfa0Q1TzVDWTd4SzZLZnc0TEp2RFNUOE80Yk5RQk1ORXBiQVZIQzUyWjl1M1dDQjVJbUxWUEZrUVBOSllZMFJ2RmtEeko4T0lPR3VnalI0N3BNbnpwZ1RrQ2RKeHBhREdyR1FfWUd3Y0pLV3F4UlpINnl1TVZhWXc1LQ?oc=5","date":"2024-11-08","type":"pipeline","source":"Reuters","summary":"Oaktree Capital urges UK's Indivior to refresh board - Reuters","headline":"Oaktree Capital urges UK's Indivior to refresh board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNLXdFM0xsX08ySHh5QmE2M2Q4TlR3cUtma1kyWEZkY3RwdGFhdVNUaXpJWHRJZjk5R3BnSzdxdndYaU9kUXNmZ25wVlVjV00wLWh1STJmUXlIQ2dXNU5DWElzY090c1NHOWxCOHRtUEZHYUhGZG1mVmpLc3hFV1pxN2xlUGhyXzhrMi05TVdVNnJIcXpXUTNsZURjWXdHSjVhc2xvTmJ4U2w4QW1sako3S0xFaGVOaEpOWVllZ2Q1dG5BUEF5YTkwcFI5N01PekNXSWUw?oc=5","date":"2024-10-10","type":"earnings","source":"Reuters","summary":"Indivior's opioid treatment sales slump prompts second profit warning - Reuters","headline":"Indivior's opioid treatment sales slump prompts second profit warning","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQT3JpVWpKUDFWNzk3U2dIZ2MwY0NwQjBnNGFxTnZZNmZjOHRiSWFuUU1saHIzaW1aSGw3a1JiYTI1WmZ3cDdOUzNzZ2doZnVfejVieTdtOEJhaTRsS3V4bTFNQVp0S25UcS1pZDk0elVNQ1ZJdUg1bjVnRjlYbnUxN1ozMjlDVTZ4S2FMMDFDQzRMc1VvSW9HMQ?oc=5","date":"2023-10-24","type":"pipeline","source":"Reuters","summary":"Indivior to pay $385 million to end final Suboxone monopoly lawsuits - Reuters","headline":"Indivior to pay $385 million to end final Suboxone monopoly lawsuits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yeWFJN3RZS0VhcTBsMV92eFppODhlZWs4X0NQSFQxVDZZU2VHSzlFVFotbEpKLUR6Y2w3dFdnVUtTemRteU9MeFNhYl9IYW54R1NJRWIzenU3R1pR?oc=5","date":"2023-06-12","type":"pipeline","source":"TradingView","summary":"INDV Stock Price and Chart — NASDAQ:INDV - TradingView","headline":"INDV Stock Price and Chart — NASDAQ:INDV","sentiment":"neutral"}],"patents":[{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"8147866","type":"Formulation","expiryDate":"2027-07-23","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"9655843","type":"Formulation","expiryDate":"2027-07-23","territory":"US","annualRevenue":800000000,"genericFilings":[]},{"drugName":"Suboxone","drugSlug":"buprenorphine/naloxone","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Subutex","drugSlug":"buprenorphine-hydrochloride","patentNumber":"9901539","type":"Method of Use","expiryDate":"2032-12-21","territory":"US","annualRevenue":800000000,"genericFilings":[]}],"drugCount":18,"phaseCounts":{"marketed":10,"phase_2":3,"phase_1":3,"phase_3":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Reckitt Benckiser","Purdue Pharma","Orexo"],"therapeuticFocus":["Addiction Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":1239000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1239000000,"period":"2025-12-31"},{"value":1188000000,"period":"2024-12-31"},{"value":1188000000,"period":"2024-12-31"},{"value":1093000000,"period":"2023-12-31"},{"value":1093000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":210000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1201000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}